This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted adult women. Participants will receive the supplement for 12 weeks, and adherence will be assessed as the percentage of doses consumed and the proportion of participants achieving ≥80% adherence. Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include changes in muscle strength, body composition, quality of life, joint pain, and skin health.
Eligibility
Sex
FEMALE
Min age
40 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Biological female sex.
* Age ≥40 years.
* Estrogen-depleted status, defined as at least one of the following:
natural menopause, defined as amenorrhea for ≥12 consecutive months; surgically induced menopause; late perimenopause with elevated FSH according to clinical judgment.
* Absence of major comorbidities that would contraindicate use of the nutritional supplement or the recommended physical activity.
* No relevant changes in usual treatment during the previous 3 months.
* Ability to understand the study information and provide written informed consent.
* Willingness to take the nutritional supplement according to the study instructions.
* Willingness to follow general physical activity recommendations provided by the investigator.
* Willingness and ability to attend the planned visits and complete study assessments through Week 12.
Exclusion Criteria:
* Initiation or modification of treatment with GLP-1 receptor agonists within the previous 12 weeks.
* Presence of musculoskeletal or joint conditions that significantly limit the ability to perform regular physical activity or study-related functional assessments.
* Clinically relevant renal or hepatic disease.
* Current use of diuretics or potentially nephrotoxic medications.
* Known allergy or intolerance to any component of the nutritional supplement.
* Participation in another clinical study (nutritional, pharmacological, or interventional) within the previous 3 months.
* Any medical condition or social circumstance that, in the investigator's judgment, could interfere with study participation, adherence, or data validity.
Primary outcome measure(s)
Adherence to Nutritional Supplementation Measured as Percentage of Prescribed Doses Consumed and Proportion of Participants Achieving ≥80% Adherence — 12 weeks Adherence to supplementation assessed as the percentage of prescribed doses consumed during the 12-week study period, based on participant self-reported daily supplementation logs. Adherence will be expressed as a continuous variable (0-100%).
In addition, the proportion of participants achieving ≥80% adherence at Week 12 will be calculated. Higher values indicate greater adherence.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.